SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer | 2026-10-15 | Option exercise | 7500 | — |
| Kelly Thomas Patrick | Chief Financial Officer | 2026-09-30 | Open-market buy | 15000 | $560K |
| MORTIMER IAN | PRESIDENT & CEO, Director | 2026-09-30 | Open-market buy | 30000 | $1.1M |
| Svoronos Dawn | Director | 2026-09-01 | Option exercise | 5144 | $42K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2026-08-28 | Open-market sell 10b5-1 | 6368 | $383K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2026-08-28 | Open-market sell 10b5-1 | 700 | $43K |
| GANNON STEVEN | Director | 2026-08-11 | Open-market sell | 10000 | $641K |
| Cannon Gillian | Director | 2026-06-05 | Open-market sell 10b5-1 | 1190 | $63K |
| PATOU GARY | Director | 2026-06-05 | Open-market sell 10b5-1 | 1322 | $70K |
| Cannon Gillian | Director | 2026-06-01 | Option exercise | 2645 | — |
| GANNON STEVEN | Director | 2026-06-01 | Option exercise | 2645 | — |
| GANNON STEVEN | Director | 2026-06-01 | Tax withholding | 1416 | $76K |
| GAROFALO ELIZABETH A. | Director | 2026-06-01 | Option exercise | 2645 | — |
| Gover Justin D. | Director | 2026-06-01 | Option exercise | 2645 | — |
| Machado Patrick | Director | 2026-06-01 | Option exercise | 2645 | — |
| PATOU GARY | Director | 2026-06-01 | Option exercise | 2645 | — |
| Svoronos Dawn | Director | 2026-06-01 | Option exercise | 2645 | — |
| Svoronos Dawn | Director | 2026-06-01 | Tax withholding | 1416 | $76K |
| GANNON STEVEN | Director | 2026-05-12 | Option exercise | 3500 | $26K |
| DiFabio Andrea | Chief Legal Officer | 2026-03-13 | Open-market sell 10b5-1 | 1342 | $74K |
Xenon Pharmaceuticals reported Q2 2026 financial results for the three and six months ended June 30, 2026, disclosing a net loss of $110.7M, R&D expenses of $99.2M, G&A expenses of $23.9M, other income of $11.8M, and a cash position of $1.245B, along with clinical development updates on its pipeline programs including azetukalner.
View raw filing on EDGAR →Xenon Pharmaceuticals held its Annual Meeting of shareholders on June 2, 2026, with voting results on six proposals including election of eight directors, advisory say-on-pay approval, say-on-pay frequency (1-year), approval of the 2026 Equity Incentive Plan, appointment of PricewaterhouseCoopers LLP as auditor, and auditor remuneration authority. All proposals passed with strong shareholder majorities.
View raw filing on EDGAR →